Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

HealthTell

Request full access

The most accurate and affordable diagnostic platform for early detection and classification of complex diseases

San Ramon, United StatesFounded 2012AI

About HealthTell

HealthTell, Inc. operated as a biotechnology firm focused on immune system profiling to facilitate early disease detection. Incorporated in 2012, the company was a spin-out from the Biodesign Institute at Arizona State University. The foundational technology, known as Immunosignature™, was developed by research scientists Stephen Albert Johnston and Neal Woodbury at ASU. Their work aimed to create a simple, inexpensive, and comprehensive method to assess health pre-symptomatically by analyzing the body's immune response.

The company's core offering was its proprietary Immunosignature™ technology, a platform designed to analyze the universe of antibodies in a single drop of blood. This was accomplished using high-density peptide arrays that act as a discovery platform, capturing patterns of antibody binding to create a unique "immunosignature" for an individual. This signature could reveal the presence of various diseases, including cancer, autoimmune disorders, and infectious diseases, with a high degree of accuracy. The technology required only a microliter of blood, which could be spotted on filter paper and mailed to their central laboratory in San Ramon, CA, for analysis.

HealthTell pursued a dual-track business model. A primary objective was the commercialization of diagnostic panels, with an initial focus on complex autoimmune diseases like lupus that are often difficult to diagnose. Simultaneously, the company established a pharmaceutical services division. This unit catered to biopharmaceutical clients, providing companion diagnostics to stratify patients for clinical trials and to identify individuals most likely to respond to specific therapies. Under the leadership of CEO Bill Colston, Ph.D., HealthTell secured significant funding, including a $14 million Series A round and a $26 million Series B round in March 2016, bringing its total raised capital to $40 million. In January 2017, HealthTell joined the Digital Life Alliance, an ecosystem of technology companies established by iCarbonX, which also became an investor. The company was ultimately acquired by iCarbonX in June 2018.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
59.3/100
Industry
Enterprise Software
Sector
Biotechnology, Oncology, Neurology, Spinout, DT and LS
Technology
Artificial Intelligence, Deep Tech, Computer Vision
Business model
SaaS
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Mar 2016 $26M $104M Third Point Ventures —
DEBT✓Debt Sep 2015 $5.2M — Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

HealthTell website traffic

Latest recorded traffic for HealthTell is 1.7K monthly website visits, up 1207.7% over the last three months. HealthTell's team grew 0% over the past year.

Latest monthly visits1.7K 3-month web change+1207.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

HealthTell in the San Ramon ecosystem

Live from Dealroom

The HealthTell office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Paladin Capital Group
  • Third Point Ventures

Other known investors3 additional known investors

Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about HealthTell on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HealthTell’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.